Format

Send to

Choose Destination
Pharmacol Res. 2016 Sep;111:721-730. doi: 10.1016/j.phrs.2016.07.021. Epub 2016 Jul 20.

Type-2 cannabinoid receptors in neurodegeneration.

Author information

1
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Italy; Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy.
2
Faculty of Veterinary Medicine, University of Teramo, Via Balzarini 1, 64100 Teramo, Italy; European Center for Brain Research/IRCCS Santa Lucia Foundation, Via del Fosso di Fiorano 64, 00143 Rome, Italy.
3
Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy.
4
Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy; European Center for Brain Research/IRCCS Santa Lucia Foundation, Via del Fosso di Fiorano 64, 00143 Rome, Italy. Electronic address: m.maccarrone@unicampus.it.

Abstract

Based on its wide expression in immune cells, type-2 cannabinoid (CB2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function. However, their recent identification in mammalian brain areas, as well as in distinct neuronal cells, has opened the way to a re-consideration of CB2 signaling in the context of brain pathophysiology, synaptic plasticity and neuroprotection. To date, accumulated evidence from several independent preclinical studies has offered new perspectives on the possible involvement of CB2 signaling in brain and spinal cord traumatic injury, as well as in the most relevant neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and Huntington's chorea. Here, we will review available information on CB2 in these disease conditions, along with data that support also its therapeutic potential to treat them.

KEYWORDS:

AM630 (PubChem CID: 4302963); Endocannabinoid system; HU-308 (PubChem CID: 101014676); JWH-015 (PubChem CID: 4273754); JWH-133 (PubChem CID: 6918505); Neurodegeneration; PF3845 (PubChem CID: 25154867); SR144528 (PubChem CID: 3081355); Type-2 cannabinoid receptors; WIN 55,212-2 (PubChem CID: 6604176)

PMID:
27450295
DOI:
10.1016/j.phrs.2016.07.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center